Clinician's Guide to Epitranscriptomics: An Example of N-Methyladenosine (mA) RNA Modification and Cancer

Overview

Journal Life (Basel)

Specialty Biology

Date 2024 Oct 26

PMID 39459530

Authors

Ana Kvolik Pavic

Josipa conkas

Ivan Mumlek

Vedran Zubcic

Petar Ozretic

Affiliations

Soon will be listed here.

Abstract

Epitranscriptomics is the study of modifications of RNA molecules by small molecular residues, such as the methyl (-CH) group. These modifications are inheritable and reversible. A specific group of enzymes called "writers" introduces the change to the RNA; "erasers" delete it, while "readers" stimulate a downstream effect. Epitranscriptomic changes are present in every type of organism from single-celled ones to plants and animals and are a key to normal development as well as pathologic processes. Oncology is a fast-paced field, where a better understanding of tumor biology and (epi)genetics is necessary to provide new therapeutic targets and better clinical outcomes. Recently, changes to the epitranscriptome have been shown to be drivers of tumorigenesis, biomarkers, and means of predicting outcomes, as well as potential therapeutic targets. In this review, we aimed to give a concise overview of epitranscriptomics in the context of neoplastic disease with a focus on N-methyladenosine (mA) modification, in layman's terms, to bring closer this omics to clinicians and their future clinical practice.

References

Fang Z, Hu Y, Hong X, Zhang X, Pan T, Pan C . Simultaneous Determination of Methylated Nucleosides by HILIC-MS/MS Revealed Their Alterations in Urine from Breast Cancer Patients. Metabolites. 2022; 12(10). PMC: 9612034. DOI: 10.3390/metabo12100973. View

Oerum S, Catala M, Atdjian C, Brachet F, Ponchon L, Barraud P . Bisubstrate analogues as structural tools to investigate mA methyltransferase active sites. RNA Biol. 2019; 16(6):798-808. PMC: 6546350. DOI: 10.1080/15476286.2019.1589360. View

Zhou H, Kimsey I, Nikolova E, Sathyamoorthy B, Grazioli G, McSally J . m(1)A and m(1)G disrupt A-RNA structure through the intrinsic instability of Hoogsteen base pairs. Nat Struct Mol Biol. 2016; 23(9):803-10. PMC: 5016226. DOI: 10.1038/nsmb.3270. View

Marikovsky M . Thiram inhibits angiogenesis and slows the development of experimental tumours in mice. Br J Cancer. 2002; 86(5):779-87. PMC: 2375322. DOI: 10.1038/sj.bjc.6600078. View

Li J, Zhang H, Wang H . N-methyladenosine modification in cancer biology: Current status and future perspectives. Comput Struct Biotechnol J. 2022; 20:6578-6585. PMC: 9712505. DOI: 10.1016/j.csbj.2022.11.045. View

Li L, Yang W, Jia D, Zheng S, Gao Y, Wang G . Establishment of a N1-methyladenosine-related risk signature for breast carcinoma by bioinformatics analysis and experimental validation. Breast Cancer. 2023; 30(4):666-684. PMC: 10284980. DOI: 10.1007/s12282-023-01458-1. View

Liu Y, Liang G, Xu H, Dong W, Dong Z, Qiu Z . Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metab. 2021; 33(6):1221-1233.e11. DOI: 10.1016/j.cmet.2021.04.001. View

Crick F . On protein synthesis. Symp Soc Exp Biol. 1958; 12:138-63. View

Cheng Q, Xiong J, Ma C, Dai Y, Ding J, Liu F . Chemical tagging for sensitive determination of uridine modifications in RNA. Chem Sci. 2021; 11(7):1878-1891. PMC: 8148390. DOI: 10.1039/c9sc05094a. View

10.

Vignon M, Bastide A, Attina A, David A, Bousquet P, Orti V . Multiplexed LC-MS/MS quantification of salivary RNA modifications in periodontitis. J Periodontal Res. 2023; 58(5):959-967. DOI: 10.1111/jre.13155. View

11.

Li Q, Huang Y, Liu X, Gan J, Chen H, Yang C . Rhein Inhibits AlkB Repair Enzymes and Sensitizes Cells to Methylated DNA Damage. J Biol Chem. 2016; 291(21):11083-93. PMC: 4900258. DOI: 10.1074/jbc.M115.711895. View

12.

Smoczynski J, Yared M, Meynier V, Barraud P, Tisne C . Advances in the Structural and Functional Understanding of mA RNA Modification. Acc Chem Res. 2024; . PMC: 10882958. DOI: 10.1021/acs.accounts.3c00568. View

13.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

14.

Wu Z, Shi Z . The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma. Eur Rev Med Pharmacol Sci. 2022; 26(16):5868-5883. DOI: 10.26355/eurrev_202208_29526. View

15.

Charette M, Gray M . Pseudouridine in RNA: what, where, how, and why. IUBMB Life. 2000; 49(5):341-51. DOI: 10.1080/152165400410182. View

16.

Gatsiou A, Stellos K . Dawn of Epitranscriptomic Medicine. Circ Genom Precis Med. 2018; 11(9):e001927. DOI: 10.1161/CIRCGEN.118.001927. View

17.

Xuan J, Chen L, Chen Z, Pang J, Huang J, Lin J . RMBase v3.0: decode the landscape, mechanisms and functions of RNA modifications. Nucleic Acids Res. 2023; 52(D1):D273-D284. PMC: 10767931. DOI: 10.1093/nar/gkad1070. View

18.

Kadaba S, Krueger A, Trice T, Krecic A, Hinnebusch A, Anderson J . Nuclear surveillance and degradation of hypomodified initiator tRNAMet in S. cerevisiae. Genes Dev. 2004; 18(11):1227-40. PMC: 420349. DOI: 10.1101/gad.1183804. View

19.

Schwartz S, Agarwala S, Mumbach M, Jovanovic M, Mertins P, Shishkin A . High-resolution mapping reveals a conserved, widespread, dynamic mRNA methylation program in yeast meiosis. Cell. 2013; 155(6):1409-21. PMC: 3956118. DOI: 10.1016/j.cell.2013.10.047. View

20.

Feng X, Chen X, Nie S, Chang Y, Meng F, Zhou J . Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia. J Cancer Res Ther. 2020; 15(7):1471-1476. DOI: 10.4103/0973-1482.204849. View